Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Global Market Report 2024

The acute lymphocytic-lymphoblastic leukemia therapeutics market size has grown strongly in recent years. It will grow from $2.68 billion in 2023 to $2.85 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to various factors, including advancements in chemotherapy, the development of biological and targeted therapies, ongoing research in pediatric oncology, improvements in supportive care, and the utilization of stem cell transplantation in the treatment of acute lymphocytic-lymphoblastic leukemia.

The acute lymphocytic-lymphoblastic leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.51 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be attributed to personalized medicine approaches tailored to individual patients, expanded access to novel therapeutic agents, global health initiatives, increased patient advocacy and awareness, and streamlined regulatory pathways. Noteworthy trends expected in the forecast period include innovation in supportive care, collaborative research efforts, advancements in diagnostic technologies, the emergence of CAR-T cell therapies, and innovations in biologics for the treatment of acute lymphocytic-lymphoblastic leukemia.

The anticipated growth of the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market is driven by the increasing prevalence of genetic conditions. Genetic conditions, resulting from mutations in an individual's DNA or genes, can lead to abnormal cell growth, potentially causing cancer. Genetic testing in acute lymphocytic-lymphoblastic leukemia aids in identifying specific genetic anomalies, informing therapeutic decisions. For example, Gene People, a UK-based charity, reported an estimated prevalence of 1 in 25 for genetic conditions in children, indicating over 2.4 million affected individuals in the UK. This prevalence highlights the role of genetic conditions in propelling the growth of the ALL therapeutics market.

The growing demand for bone marrow transplantation is poised to be a significant driver for the acute lymphocytic-lymphoblastic leukemia therapeutics market. Bone marrow transplantation, replacing damaged or diseased bone marrow with healthy hematopoietic stem cells, offers benefits such as higher remission rates and potential cures. In the United States, Health Resources and Services Administration data from June 2023 revealed 5,073 unrelated and 4,276 related bone marrow and cord blood transplants in 2021. The increasing demand is evident from the rise in registered donors from 9,285,029 in 2021 to 9,475,534 in 2022. This underscores the impact of bone marrow transplantation in driving the growth of the ALL therapeutics market.

The high cost of treatment is expected to impede the growth of the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market. This financial burden includes the costs associated with diagnosing and treating leukemia, varying depending on the leukemia type and treatment phase. According to the National Cancer Institute's August 2023 data, annualized average costs for medical services and oral prescription drugs in the United States show considerable variation. The high treatment costs pose challenges for patients and their families, hindering the market's growth.

Major companies in the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market are actively developing innovative therapies to address consumer needs. Tecartus (brexucabtagene autoleucel) by Kite Pharma is a notable example, utilizing chimeric antigen receptor (CAR) T-cell therapy. Tecartus, approved by the Food and Drug Administration in November 2021, is a CD19-directed genetically modified autologous T-cell immunotherapy. This CAR T-cell therapy has expanded treatment options for adults with ALL, showcasing Kite Pharma's expertise in cell therapy and contributing to revenue growth.

In April 2021, Artios Pharma Limited, a UK-based pharmaceutical company, collaborated with Novartis AG to develop DDR cancer therapies. This collaboration combines Novartis' radioligand therapeutics with Artios Pharma's discovery platform to target DNA damage response (DDR) and advance novel cancer medicines. Novartis AG's contributions to the field include advancements in treatments for blood malignancies such as acute lymphocytic or lymphoblastic leukemia (ALL).

Major companies operating in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Astellas Pharma Inc., Eisai Co. Ltd., Jazz Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Genmab A/S, Kite Pharma, ADC Therapeutics, Kiadis Pharma, SymBio Pharmaceuticals Limited, Celyad Oncology SA, Precigen Inc., Leadiant Biosciences Inc., Medexus Pharma Inc., Spectrum Pharmaceuticals Inc., OBI Pharma Inc.

North America was the largest region in the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market includes revenues earned by entities by providing services such as laboratory testing, molecular diagnostics, chemotherapy administration, targeted therapy, blood and platelet transfusions, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market also includes sales of Arranon (nelarabine), Asparaginase erwinia chrysanthemi, Asparlas (calaspargase pegol-mknl), Besponsa (inotuzumab ozogamicin), and Blincyto (blinatumomab). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary therapeutic modalities for acute lymphocytic-lymphoblastic leukemia include chemotherapy, targeted therapy, radiation therapy, and stem cell transplantation. Chemotherapy is a systemic treatment that utilizes drugs to destroy or inhibit the growth of rapidly dividing cells, including cancer cells. The diagnostic procedures for ALL involve various tests such as biopsy and bone marrow aspiration, complete blood count (CBC) and differential, assessment for the presence of the Philadelphia chromosome, spinal tap and cerebrospinal fluid (CSF) analysis, and immunophenotyping or phenotyping by flow cytometry. Additionally, molecular diagnostic techniques such as polymerase chain reaction (PCR) are used. Acute lymphocytic-lymphoblastic leukemia can be diagnosed in various cell types, including the Philadelphia chromosome, precursor B-cell ALL, and T-cell ALL. The administration routes for treatment include oral and parenteral, catering to both pediatric and adult age groups.

The acute lymphocytic-lymphoblastic leukemia therapeutics market research report is one of a series of new reports that provides acute lymphocytic-lymphoblastic leukemia therapeutics market statistics, including acute lymphocytic-lymphoblastic leukemia therapeutics industry global market size, regional shares, competitors with an acute lymphocytic-lymphoblastic leukemia therapeutics market share, detailed acute lymphocytic-lymphoblastic leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the acute lymphocytic-lymphoblastic leukemia therapeutics industry. This acute lymphocytic-lymphoblastic leukemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.